The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis.

Eli Lilly & Co.’s blockbuster obesity shot Zepbound helped people with type 1 diabetes lose more than a fifth of their body weight over a yearlong study, suggesting the drug may help patients with the less common autoimmune form of the disease.

Results from 4 studies revealed that women lost more weight on average than men when taking tirzepatide — but they also reported more side effects.

A new study found that women using the weight loss drug tirzepatide (Mounjaro) lost more weight than men, but experienced higher rates of side effects like nausea and vomiting.